Sexuality and the management of BPH with alfuzosin (SAMBA) trial

B. H. Chung, J. Y. Lee, C. I. Kim, C. S. Kim, C. Y. Oh, S. W. Lee, J. S. Lee, S. J. Yoo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function scales: male sexual health questionnaire (MSHQ) and international index of erectile function (IIEF-15). A total of 148 patients with BPH were treated with alfuzosin for 24 weeks. The patients were followed at baseline, 4, 12 and 24 weeks after medication with alfuzosin. MSHQ was collected at every visit, whereas Qmax, IPSS and IIEF-15 were checked at baseline and end point. At the end point, Q max (+4.7 ml s-1, P<0.01) and IPSS (-5.3, P<0.01) had improved significantly. Alfuzosin also significantly improved the total MSHQ (19.2%, 79.1-94.3, P<0.01) and the MSHQ ejaculatory scores (26.0%, 22.3-28.1, P=<0.01) versus baseline. Alfuzosin for the treatment of patients with BPH is effective in improving sexual function, as well as lower urinary tract symptoms (LUTSs) and quality of life, and is well tolerated.

Original languageEnglish
Pages (from-to)68-73
Number of pages6
JournalInternational Journal of Impotence Research
Volume21
Issue number1
DOIs
Publication statusPublished - 2009 Jan 1

Fingerprint

Prostatic Hyperplasia
Sexuality
Reproductive Health
Lower Urinary Tract Symptoms
alfuzosin
Quality of Life
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Chung, B. H. ; Lee, J. Y. ; Kim, C. I. ; Kim, C. S. ; Oh, C. Y. ; Lee, S. W. ; Lee, J. S. ; Yoo, S. J. / Sexuality and the management of BPH with alfuzosin (SAMBA) trial. In: International Journal of Impotence Research. 2009 ; Vol. 21, No. 1. pp. 68-73.
@article{f669bc2f058d4872a4fcc276f42f17be,
title = "Sexuality and the management of BPH with alfuzosin (SAMBA) trial",
abstract = "The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function scales: male sexual health questionnaire (MSHQ) and international index of erectile function (IIEF-15). A total of 148 patients with BPH were treated with alfuzosin for 24 weeks. The patients were followed at baseline, 4, 12 and 24 weeks after medication with alfuzosin. MSHQ was collected at every visit, whereas Qmax, IPSS and IIEF-15 were checked at baseline and end point. At the end point, Q max (+4.7 ml s-1, P<0.01) and IPSS (-5.3, P<0.01) had improved significantly. Alfuzosin also significantly improved the total MSHQ (19.2{\%}, 79.1-94.3, P<0.01) and the MSHQ ejaculatory scores (26.0{\%}, 22.3-28.1, P=<0.01) versus baseline. Alfuzosin for the treatment of patients with BPH is effective in improving sexual function, as well as lower urinary tract symptoms (LUTSs) and quality of life, and is well tolerated.",
author = "Chung, {B. H.} and Lee, {J. Y.} and Kim, {C. I.} and Kim, {C. S.} and Oh, {C. Y.} and Lee, {S. W.} and Lee, {J. S.} and Yoo, {S. J.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/ijir.2008.62",
language = "English",
volume = "21",
pages = "68--73",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "1",

}

Chung, BH, Lee, JY, Kim, CI, Kim, CS, Oh, CY, Lee, SW, Lee, JS & Yoo, SJ 2009, 'Sexuality and the management of BPH with alfuzosin (SAMBA) trial', International Journal of Impotence Research, vol. 21, no. 1, pp. 68-73. https://doi.org/10.1038/ijir.2008.62

Sexuality and the management of BPH with alfuzosin (SAMBA) trial. / Chung, B. H.; Lee, J. Y.; Kim, C. I.; Kim, C. S.; Oh, C. Y.; Lee, S. W.; Lee, J. S.; Yoo, S. J.

In: International Journal of Impotence Research, Vol. 21, No. 1, 01.01.2009, p. 68-73.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sexuality and the management of BPH with alfuzosin (SAMBA) trial

AU - Chung, B. H.

AU - Lee, J. Y.

AU - Kim, C. I.

AU - Kim, C. S.

AU - Oh, C. Y.

AU - Lee, S. W.

AU - Lee, J. S.

AU - Yoo, S. J.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function scales: male sexual health questionnaire (MSHQ) and international index of erectile function (IIEF-15). A total of 148 patients with BPH were treated with alfuzosin for 24 weeks. The patients were followed at baseline, 4, 12 and 24 weeks after medication with alfuzosin. MSHQ was collected at every visit, whereas Qmax, IPSS and IIEF-15 were checked at baseline and end point. At the end point, Q max (+4.7 ml s-1, P<0.01) and IPSS (-5.3, P<0.01) had improved significantly. Alfuzosin also significantly improved the total MSHQ (19.2%, 79.1-94.3, P<0.01) and the MSHQ ejaculatory scores (26.0%, 22.3-28.1, P=<0.01) versus baseline. Alfuzosin for the treatment of patients with BPH is effective in improving sexual function, as well as lower urinary tract symptoms (LUTSs) and quality of life, and is well tolerated.

AB - The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function scales: male sexual health questionnaire (MSHQ) and international index of erectile function (IIEF-15). A total of 148 patients with BPH were treated with alfuzosin for 24 weeks. The patients were followed at baseline, 4, 12 and 24 weeks after medication with alfuzosin. MSHQ was collected at every visit, whereas Qmax, IPSS and IIEF-15 were checked at baseline and end point. At the end point, Q max (+4.7 ml s-1, P<0.01) and IPSS (-5.3, P<0.01) had improved significantly. Alfuzosin also significantly improved the total MSHQ (19.2%, 79.1-94.3, P<0.01) and the MSHQ ejaculatory scores (26.0%, 22.3-28.1, P=<0.01) versus baseline. Alfuzosin for the treatment of patients with BPH is effective in improving sexual function, as well as lower urinary tract symptoms (LUTSs) and quality of life, and is well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=58149498318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149498318&partnerID=8YFLogxK

U2 - 10.1038/ijir.2008.62

DO - 10.1038/ijir.2008.62

M3 - Article

C2 - 19078970

AN - SCOPUS:58149498318

VL - 21

SP - 68

EP - 73

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 1

ER -